NCR1 and melanoma: For all three groups of melanoma-bearing mice, regardless of TLR 7/8 agonist treatment, we observed a significant decrease in the expression of the activating receptor NKp46 compared to healthy mice (PBS, p < 0.05; IMQ, p < 0.01; GDQ, p < 0.05) (Figure 7a), but no significant differences were observed after treatment with the indicated agonists compared to the vehicle control (PBS).